pharmaphorum

This Friday, a woman from the Wirral in the #UK has become the #firstpatient in the world to receive an experimental, personalised #lungcancervaccine. In other news today, #AstraZeneca and #DaiichiSankyo's #Datroway has entered the first-line #triplenegativebreastcancer market in the EU, taking on Gilead's Trodelvy. Elsewhere, #Pfizer's #JAKinhibitor #Litfulo has hit the mark in #vitiligo, setting up filings, while #Incyte has claimed #EU approval for #Opzelura in #atopicdermatitis. Meanwhile, #Replimune's RP1 #immunotherapy for #melanoma has cleared an advisory committee vote by 10 to three, despite #FDA concerns about the design of the IGNYTE study. And #sleepapnoea drug developer #Apnimed has completed its #IPO, raising $192 million, while #Braveheart, #Attovia, and #Vogenx reveal their terms. For those wanting a longer read today, discover why #patientaccess is broken. Discover all this and more at https://pharmaphorum.com

Circulating tumour DNA has emerged as a promising primary surrogate endpoint in solid tumour oncology. In a new article from ICON plc, Dr Bea Mann, senior director and oncology therapeutic expert at ICON explores what's needed to establish #ctDNA a validated surrogate endpoint. https://lnkd.in/em5Jn7wY

This Thursday, #JohnsonandJohnson has bid for a slice of the #invivo #CART category, signing an alliance with #SailBio that could evolve into a $2.58 billion takeover. In other news today, four #Democraticsenators are investigating whether the family of #HHS Secretary Robert F #Kennedy Jr is profiting from what they assert are "bogus" #vaccine #lawsuits. Elsewhere, shortly after terminating one late-stage R&D programme, #Sanofi has confirmed in its #secondquarterupdate that two others are also being scrapped. Meanwhile, #FDA advisors have voted that #Capricor has not shown #efficacy for #deramiocel in #Duchenne muscular dystrophy, due to altered endpoints in its main trial. And #Cytokinetics has received simultaneous #MHRA and #NICE #approvals for #hypertrophiccardiomyopathy therapy #Myqorzo. For those wanting a longer read today, find out more about why the most important #researchanddevelopment decisions happen during the pauses between documented steps. We’ve also a new episode of the pharmaphorum #podcast: #AliceValderCurran of Hogan Lovells returns to discuss the new communication from #CMS on #drugpricenegotiation. Discover all this and more at https://pharmaphorum.com

This Wednesday, a #US judge has ruled that #NovoNordisk must face a #lawsuit claiming it defrauded investors with misleading statements about a pivotal #CagriSema study. In other news today, #AbbVie's fast-growing #JAKinhibitor #Rinvoq has been cleared for #alopeciaareata in the #EU, its first market for the #hairloss disorder. Elsewhere, #Altimmune's #pemvidutide has been shown to reduce drinking in people with #alcoholusedisorder, adding to the evidence for #GLP1 drugs in this setting. Meanwhile, #Biogen/#Eisai's #Alzheimers drug #Leqembi continued to grow in Q2, driven by a new #subcutaneous version, but fell a little short of expectations. And a #bloodtest for #tuberculosis that can distinguish between dormant and active infections has shown promise in a clinical trial. For those wanting a longer read today, learn why #patientaccess will not improve without better #digital foundations. Discover all this and more at https://pharmaphorum.com

This Tuesday, #JohnsonandJohnson has made a $5.5 billion bid to finally bring more than 15 years of #litigation over the safety of its #talcumpowder products to a close. In other news today, an #HIV resurgence is looming as #internationalaid declines, with the Joint United Nations Program on HIV/AIDS (#UNAIDS) stating that more than 3 million people worldwide could be infected with HIV by the end of the decade. Elsewhere, in a major shake-up of its #UK operations, #GSK is building a brand new R&D centre in #Cambridge and transferring operations there from its #Stevenage campus. Meanwhile, gene-editing specialist #Scribe has become the 14th #biotech to list on the #Nasdaq this year, raising $155 million in #IPO, and #sleepapnoea drug developer #Apnimed has priced its listing also. And around five months after long-serving CEO Doug Ingram said he was stepping down, #SareptaTherapeutics has named industry veteran #MichaelSeverino to replace him. For those wanting a longer read today, learn more about why the creation of a #SinglePatientRecord (SPR) is one of the most significant reforms to #healthdata in a generation. And discover key insights from #AxtriaIgnite 2026, where experts explored how culture, training, and strategy create competitive advantage in an increasingly commodified #AI world. Discover all this and more at https://pharmaphorum.com

As the long, hot summer continues, make sure you stay up-to-date with pharmaphorum's #editorial and #thoughtleadership content.   If you missed new features from 20th to 24th July, then catch up on your reading here! #pharmareads   Early diagnosis means little without timely treatment 🖊️ Sasha Burns 👉 https://lnkd.in/d7_mvk2c   Drug discovery has a human biology problem 🖊️ Emma Pepperell 👉 https://lnkd.in/dMr7aR3a   Progress with England’s Single National Formulary after a year 🖊️ Leela Barham 👉 https://lnkd.in/dzEgts87   Why trust is becoming pharma’s most important visibility metric 🖊️ Chris Pearce 👉 https://lnkd.in/daA6UWPj   Moving beyond intent: Building more diverse clinical trials 🖊️ Shambhavi Chidambaram, PhD 👉 https://lnkd.in/d5BAeaK4   Why Britain's blood tests are only as reliable as the journey to the lab 🖊️ Kevin Moore UCL 👉 https://lnkd.in/dPd9Yy6x

At Axtria - Ingenious Insights Ignite 2026, #AI executives from top #lifesciences, #pharma, and #medtech companies came together to share their experiences and get to the bottom of what it really takes to create scalable AI deployments that bring real, measurable #ROI. Discover more about their insights here. https://lnkd.in/gAkDm9T4

As #oncology shifts towards precision medicine, researchers are exploring the promise of ctDNA as a validated primary surrogate endpoint. In a new article from ICON plc, Dr Bea Mann, senior director and oncology therapeutic expert at ICON, explores why #ctDNA is attracting growing interest and what still needs to happen before it can be widely adopted in solid tumour drug development. https://lnkd.in/em5Jn7wY

This Friday, the recently revamped #FDA Pharmacy Compounding Advisory Committee has narrowly voted in favour of loosening restrictions on peptide therapies, despite FDA staff scientists’ warnings that such #peptides lack safety and efficacy evidence. In other news today, Johnson & Johnson is celebrating multiple phase 3 wins after two of its multiple #myeloma therapies – Tecvayli and Talvey – showed a dramatic improvement in overall survival when used as a combination therapy. Elsewhere, #Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare infant-affecting liver disease with limited treatment options. Meanwhile, in a major blow to what was once viewed as a 'pipeline-in-a-product', #Sanofi has halted development of anti-OX40L drug amlitelimab in atopic dermatitis. And, the FDA has named #Dexcom as the first medical device firm to take part in its TEMPO pilot programme, which aims to bring digital health tech to patients more quickly.